Sanne Gisela Johanna Mourmans

Sanne Gisela Johanna Mourmans

Auto-generated profile, based on publicly available information

Sanne Gisela Johanna Mourmans

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+) , Maastricht

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Jerremy WeertsJerremy Weerts
Jerremy Weerts
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
MAMiren Arantzazu Barandiaran Aizpurua
Miren Arantzazu Barandiaran Aizpurua
BSBlanche Schroen
Blanche Schroen
CKChristian Knackstedt
Christian Knackstedt
VEVanessa P. M. van Empel
Vanessa P. M. van Empel
Heart failure with preserved ejection fraction (HFpEF) is a condition with increasing incidence, leading to a health care problem of epidemic proportions for which no curative treatments exist. Consequently, an urge exists to better understand the pathophysiology of HFpEF. Accumulating evidence suggests a key pathophysiological role for coronary microvascular dysfunction (MVD), with an underlying mechanism of low-grade pro-inflammatory state caused by systemic comorbidities. The systemic entity of comorbidities and inflammation in HFpEF imply that patients develop HFpEF due to systemic mechanisms causing coronary MVD, or systemic MVD. The absence or presence of peripheral MVD in HFpEF would reflect HFpEF being predominantly a cardiac or a systemic disease. Here, we will review the current state of the art of cardiac and systemic microvascular dysfunction in HFpEF (Graphical Abstract), resulting in future perspectives on new diagnostic modalities and therapeutic strategies.

5 April 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
NVNousjka P. A. Vranken
Nousjka P. A. Vranken
XLXinyu Li
Xinyu Li
HBHeleen Bouman
Heleen Bouman
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
AAAnouk Achten
Anouk Achten
Jerremy WeertsJerremy Weerts
Jerremy Weerts
Background: Most patients with heart failure with preserved ejection fraction (HFpEF) have a metabolic phenotype in which comorbidities including diabetes mellitus play an important role. Factors related to impaired glucose metabolism, such as kidney disease, may contribute to adverse clinical events. Albuminuria is an early marker of kidney disease. We assessed the prevalence of impaired glucose metabolism and albuminuria in HFpEF over time, and evaluated its prognostic implications. Methods: Consecutive patients referred to our outpatient clinic and diagnosed with HFpEF between March 2015–November 2023 were included in this study. Patients with type 1 diabetes were excluded. Patients were stratified according to baseline glucose metabolism status (DM + for prediabetes and diabetes, or DM−) and albuminuria status (ALB+ or ALB− for albuminuria > 3.0 mg/mmol and normoalbuminuria, respectively). The primary outcome was a composite of HF hospitalizations (HFH) and all-cause mortality, and was analysed using multivariable-adjusted Cox-regression models. Results: Among 332 patients with HFpEF (median age 77 years; 67% female), 121 (36.4%) were classified as DM−/ALB−, 106 (31.9%) as DM+ /ALB−, 44 (13.3%) as DM−/ALB+, and 61 (18.4%) as DM+ /ALB+. Both baseline DM and ALB were independently associated with the primary outcome after approximately 3 years: adjusted hazard ratio (aHR) 1.93; 95% confidence interval (CI) 1.25–2.97 and 1.58; 95%CI 1.04–2.41, respectively. Patients in the DM+ /ALB+ group showed the highest risk (aHR 2.85; 95%CI 1.57–5.15). After one year, DM/ALB status was re-evaluated in 250 (75%) patients. New DM+ and ALB+ incidence was 3.9% and 22%in those at risk, respectively. Patients particularly changed ALB groups compared to baseline (n = 63, 25.2%); 27 (10.8%) patients recovered from albuminuria. At 3 years follow-up, the primary outcome mainly occurred in patients who consistently showed albuminuria (27.1%) or who recovered from albuminuria (22.2%), and less so in patients who developed albuminuria after one year (13.9%) or who remained free of albuminuria (8.6%) (p = 0.008). Conclusions: DM and albuminuria are prevalent in HFpEF at baseline, and re-evaluation one year later still reveals new diagnoses. Both factors are independently associated with adverse outcomes. Albuminuria at any time point remains predictive of adverse outcomes in HFpEF. Graphical Research insights: What is currently known about this topic?: Diabetes mellitus is an important cardiovascular risk factor in patients with HFpEF, contributing to disease progression and worse outcomes. Albuminuria is a prognostic marker in heart failure patients and more prevalent in patients with diabetes What is the key research question?: What is prevalence of impaired glucose metabolism and albuminuria in HFpEF over time and how does this translate to prognosis? What is new?: Both DM and albuminuria each independently associated with worse prognosis in HFpEF. Screening 1 year after HFpEF diagnosis yielded incidence rates of 3.9% and 10.8% for DM and prediabetes, respectively, and 22% for albuminuria. Albuminuria at any time point appeared prognostic in HFpEF, also when albuminuria recovered How might this study influence clinical practice?: Intermittent screening of HFpEF patients for abnormal glucose metabolism and albuminuria is warranted to optimize risk management

25 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jerremy WeertsJerremy Weerts
Jerremy Weerts
ARAnne Raafs
Anne Raafs
BSBirgit Sandhoefner
Birgit Sandhoefner
FBFrank van de Baan
Frank van de Baan
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
SHStephane Heymans
Stephane Heymans
Background: Systemic microvascular regression and dysfunction are considered important underlying mechanisms in heart failure with preserved ejection fraction (HFpEF), but retinal changes are unknown. Methods: This prospective study aimed to investigate whether retinal microvascular and structural parameters assessed using optical coherence tomography angiography (OCT-A) differ between patients with HFpEF and control individuals (i.e., capillary vessel density, thickness of retina layers). We also aimed to assess the associations of retinal parameters with clinical and echocardiographic parameters in HFpEF. HFpEF patients, but not controls, underwent echocardiography. Macula-centered 6 × 6 mm volume scans were computed of both eyes. Results: Twenty-two HFpEF patients and 24 controls without known HFpEF were evaluated, with an age of 74 [68–80] vs. 68 [58–77] years (p = 0.027), and 73% vs. 42% females (p = 0.034), respectively. HFpEF patients showed vascular degeneration compared to controls, depicted by lower macular vessel density (p < 0.001) and macular ganglion cell-inner plexiform layer thickness (p = 0.025), and a trend towards lower total retinal volume (p = 0.050) on OCT-A. In HFpEF, a lower total retinal volume was associated with markers of diastolic dysfunction (septal e’, septal and average E/e’: R2 = 0.38, 0.36, 0.25, respectively; all p < 0.05), even after adjustment for age, sex, diabetes mellitus, or atrial fibrillation. Conclusions: Patients with HFpEF showed clear levels of retinal vascular changes compared to control individuals, and retinal alterations appeared to be associated with markers of more severe diastolic dysfunction in HFpEF. OCT-A may therefore be a promising technique for monitoring systemic microvascular regression and cardiac diastolic dysfunction.

1 October 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
JWJanneke Woudstra Janneke Woudstra
Janneke Woudstra Janneke Woudstra
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
CVCaitlin E. M. Vink
Caitlin E. M. Vink
KMKoen M. J. Marques
Koen M. J. Marques
EJElize A. M. de Jong
Elize A. M. de Jong
OCon behalf of the IMPRESS consortium
on behalf of the IMPRESS consortium
This study provides proof of concept that assessment of the peripheral vasculature, particularly vascular smooth muscle cells measured using the LASCA technology holds potential as a noninvasive tool for detecting coronary vasomotor dysfunction. This finding highlights the potential of the LASCA technology in, for example, medication studies for coronary vasomotor dysfunction, especially when investigating whether medication improves vascular function, as repeated peripheral measurements are less invasive than invasive coronary function testing, the current gold standard.

19 May 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
Jerremy WeertsJerremy Weerts
Jerremy Weerts
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
RPRavi B. Patel
Ravi B. Patel
ABArno A. van de Bovenkamp
Arno A. van de Bovenkamp
HAHesam Amin
Hesam Amin
VEVanessa P.M. van Empel
Vanessa P.M. van Empel
Heart failure with preserved ejection fraction (HFpEF) is common but diagnosing it remains cumbersome and complex. Left atrial (LA) enlargement and dysfunction is an important pathologic marker in HFpEF. We evaluated whether LA measures and circulating natriuretic peptides (NPs) could simplify HFpEF diagnosis as a first step. A new, first-step diagnostic approach to rule in HFpEF is presented using LA volume indexed for height2 (LAViH2; cut-off >35.5 ml/m2 in sinus rhythm, or >38.6 ml/m2 in atrial fibrillation) and NPs (as per the HFA-PEFF major criterion). The LA/NP approach was derived from 443 patients with suspected of HFpEF (final diagnosis 84% HFpEF, 16% controls without heart failure), and validated in two independent cohorts (503 patients, 90% HFpEF; and 123 patients undergoing (exercise) right heart catheterization, 86% HFpEF). The LA/NP step identified 60% HFpEF patients with 88% specificity and 97% positive predictive value (PPV) (derivation cohort). Sequentially applying the LA/NP step, and if normal followed by either HFA-PEFF or H2FPEF algorithm, reduced intermediate HFpEF likelihood scores compared to starting with the algorithms, decreasing additional diagnostic needs for HFpEF diagnosis by 27% (HFA-PEFF) and 56% (H2FPEF). Validation cohorts confirmed the LA/NP approach (76-80% specificity, 92-97% PPV, and 21-57% reduction in intermediate scores). Replacing LAViH2 with LA reservoir strain showed comparable results. A first-step approach using enlarged LA volume and elevated NPs simplifies HFpEF diagnosis. This approach identifies most HFpEF patients with high specificity and substantially reduces the need for additional diagnostics by lowering intermediate HFA-PEFF or H2FPEF scores.

1 December 2024 in ESC Heart Failure
Verified
Journal Article
Open access
Jerremy WeertsJerremy Weerts
Jerremy Weerts
SMSanne G.J. Mourmans
Sanne G.J. Mourmans
HLHelena Lopez-Martinez
Helena Lopez-Martinez
MDMar Domingo
Mar Domingo
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
VEVanessa P.M. van Empel
Vanessa P.M. van Empel
Aims: Inter-atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown. The aim of this study is to determine the prevalence of IAB and the association of IAB and AF with adverse events in HFpEF across different healthcare settings. Methods and results: To identify electrical atrial dysfunction, baseline ECG's and medical history were analysed in HFpEF patients in an ambulatory setting and after recent HF hospitalisation. Patients were categorised into (i) HFpEFNo IAB, (ii) HFpEFIAB, or (iii) HFpEFAF. Adverse events included HF hospitalisation, cardiac/sudden death and a composite of both. The ambulatory cohort included 372 patients [mean age 75 ± 7 years, 252 (68%) females]. The recently hospitalised cohort included 132 patients [mean age 81 ± 10 years, 80 (61%) females]. Ambulatory patients included 17 (4%) HFpEFnoIAB, 114 (31%) HFpEFIAB and 241 (65%) HFpEFAF, while recently hospitalised patients included 31 (23%), 73 (55%) and 28 (21%), respectively. After 33 months of follow-up of ambulatory patients, composite endpoints occurred in 0 (0%) HFpEFnoIAB, 12 (11%) HFpEFIAB [HR 4.1 (95% CI 0.5–522.6)] and 59 (24%) HFpEFAF patients [HR 10.1 (95% CI 1.5–1270.4), P < 0.001]. Recently hospitalised patients showed a similar trend, with composite endpoints in 10 (32%) HFpEFnoIAB, 31 (42%) HFpEFIAB (HR 1.5 [95% CI 0.7–3.1]) and 22 (79%) HFpEFAF (HR 3.8 [95% CI 1.8–8.1], P < 0.001). Conclusions: Progressive stages of electrical atrial dysfunction appeared to be prognostic markers of adverse outcomes in ambulatory and recently hospitalised patients with HFpEF. Ambulatory patients with HFpEF and no early stages of electrical atrial dysfunction showed to be at very low risk for adverse outcomes. Whether such patients benefit less strict management remains to be investigated.